M42 Health✓

A milestone for clinical research in the UAE. IROS, part of M42, is partnering with Mammoth Biosciences to conduct the UAE’s first clinical trial evaluating an advanced gene-editing therapy. Supported by the Department of Health - Abu Dhabi, this trial investigates a single-infusion treatment aimed at addressing the root genetic cause of dangerously high blood triglycerides. By connecting advances in genomics with clinical innovation, we are turning science into world solutions and personalizing healthcare in Abu Dhabi. #M42 #FutureHealthSummit2026

Building the future of healthcare talent in the UAE. We have signed a Memorandum of Understanding with the American University in Dubai to expand practical learning, research and clinical observation opportunities for biology and pre-medical students. Through this collaboration, students will gain direct insight into M42 facilities across neuroscience, cancer, metabolic and cardiovascular health alongside digital health and genomics, gaining experience in different fields and potential career pathways. This initiative aims to connect academic study with real-world healthcare delivery while supporting UAE national workforce development and Emiratization priorities. Learn more through the link #M42 #FutureHealthSummit2026

The next generation of healthcare talent. Our new partnership with the American University in Dubai brings biology and pre-med students into our facilities for real-world learning, research, and clinical exposure as we continue to attract the region's best future talent. This collaboration aims to develop local expertise, support UAE national workforce development and Emiratization priorities. Find out more through the link #M42 #FutureHealthSummit2026

As GLP-1 weight loss therapies grow globally, making sure people stay properly nourished is key. When your appetite drops, it is easy to miss out on nutritional values that your body needs to thrive. That is why our research team at IROS is partnering with 10XREVIV on a new clinical study. The study will assess whether 10XREVIV’s precision nutrition system can help address micronutrient deficiencies and improve patient well-being during treatment. It also highlights Abu Dhabi’s growing capabilities in clinical research and its role in evaluating precision health solutions that address emerging healthcare needs. #M42 #FutureHealthSummit2026

RT @MasdarCity: Big ideas. Even better conversations. 🧬 BioConnect brought innovators, clinicians, regulators and investors together at Masdar City on October 19 to talk about the future of life sciences in Abu Dhabi.

In our partnership with the ADQCC, we are showcasing the Central Testing Lab’s honey testing capabilities at the fifth edition of Al Dhafra Dates Festival and Auction in Madinat Zayed, Al Dhafra. Honey production is rooted in the UAE’s agricultural heritage. Through M42’s Environmental Sciences’ partnerships and its highest honey quality laboratory, advanced testing is applied to assess the purity, moisture levels and sugar contents across local Sidr, Samar and honeycomb varieties. Independent testing by CTL brings integrity to the festival and builds lasting trust in homegrown honey. Find us at Stand No. 3 until the 25th of October to learn more and have your honey tested, with results available in just seven days. #M42 #QCC #CTL

RT @G42ai: From Abu Dhabi to Athens. The next chapter of AI cooperation.

G42 and five of our portfolio companies have signed strategic MoUs with Greek government and private-sector partners, opening new opportunities for AI infrastructure and applications across Greece.

Signed during the UAE’s official trade delegation visit to Athens, the agreements bring together the capabilities of @khazna_dc, @core42_ai, @PresightAI, @Inception_42 and @M42Health to explore:

• Developing an AI factory with Copelouzos Group, combining data center infrastructure, cloud and advanced compute.

• Applying AI to smarter cities, government operations and education.

• Advancing life sciences research, genomics and healthcare innovation.

Together, these initiatives reflect our Intelligence Grid vision, connecting infrastructure, compute and practical applications to make intelligence accessible at scale.

Built on the growing partnership between the UAE and Greece, this collaboration represents another step towards expanding AI capabilities across Europe, in alignment with European standards.

New partnerships. New possibilities. One shared ambition to advance AI for everyone.

Read more:

#G42ai #ExponentialAI #AI #IntelligenceGrid #Greece

M42’s Healthpoint has signed a Memorandum of Understanding with Proximie to introduce advanced AI intelligence across its operating rooms in Abu Dhabi. Healthpoint becomes the first hospital in the M42 infrastructure to implement this technology, supported by AWS cloud network. By capturing surgical phases, the platform equips surgical teams with the insight to anticipate potential delays, coordinate care more effectively, and optimize operating theater capacity. It is another milestone in how we are using predictive, precision-led technology into everyday clinical workflows to deliver smoother, safer care for every patient. #M42 #FutureHealthSummit2026

Catching cancer recurrence earlier changes everything. At the Future Health Summit, we announced a collaboration with Inocras to bring whole genome powered blood monitoring to the UAE. Starting with a breast cancer trial at Cleveland Clinic Abu Dhabi, this advanced technology tracks tiny traces of cancer DNA in the blood months before anything shows up on standard scans. By spotting these signs earlier, doctors can step in faster and give patients more targeted, proactive care when it matters most. It is another major step in our mission to build a complete precision oncology pathway. To discover more, click the link #M42 #FutureHealthSummit2026

Connecting Abu Dhabi and Athens to accelerate the journey from scientific discovery to better health. M42 was proud to join the UAE’s official visit to Athens, Greece led by the United Arab Emirates Ministry of Foreign Trade, which included the UAE-Greece Business Forum. With G42 and its portfolio companies, Khazna Data Centers, Core42, Presight and Inception 42, M42 also helped extend G42’s Intelligence Grid proposition into Greece. M42’s Dimitris Moulavasilis and Athens LifeTech Park’s Eleni Pentafragka signed a Memorandum of Understanding to advance collaboration across life sciences research, genomics sequencing infrastructure, population genomics, clinical development and connected institutional biobanks. The partnership will open opportunities for joint translational research, preclinical studies and integrated genomics, multi-omics and biomarker research, with a focus on oncology, rare genetic diseases and neuroscience. It also creates a two-way bridge for innovation: • UAE life sciences start-ups will gain a base at the Athens LifeTech Park Incubator to support European market entry • Greek and European ventures will gain opportunities for collaboration and access to the UAE through M42’s network. “The next era of global health will be led by ecosystems with a shared purpose that cross borders,” said Dimitris Moulavasilis, Group CEO of M42. By connecting Abu Dhabi’s clinical, genomic and technology infrastructure with Greece’s scientific capabilities and European reach, we aim to translate shared ambition into joint research, stronger ventures and discoveries that improve lives. #M42 #G42 #LifeSciences #Genomics #HealthInnovation

The future of health is a collective effort. At the Abu Dhabi Future Health Summit 2026, M42 joined global leaders, innovators and partners to explore new possibilities for healthcare and turn shared ambition into meaningful progress. Because advancing health takes more than innovation alone. It takes collaboration across disciplines, technologies and borders to make better health outcomes possible for more people. As we look ahead, M42 remains focused on connecting the capabilities that can help transform healthcare, in the UAE and around the world. #M42 #FutureHealthSummit2026

In the presence of Sheikh Mohamed bin Saeed Al Nahyan and Sheikh Zayed bin Mansour bin Tahnoon Al Nahyan, M42 and 26 Labs, an Emirati health innovation hub, have signed an agreement to advance the deployment of digital health solutions, with a focus on the launch and implementation of the Smart Mirror. The agreement was signed by Kareem Shahin, Chief Executive Officer, Digital Health Solutions Platform and Group Chief Digital Officer, M42, and Abdulla AbuEbeid, Chief Executive Officer of VIAI; Afra Al Ahbabi, Founder and Chief Executive Officer of NABDH; and Mohammed Obaid Al Ketbi, Chief Executive Officer of Dr. O Hub, each in their respective capacities in connection with the collaboration between M42 and 26 Labs. The signing marks a further step towards advancing digital health innovation and the implementation of technology-driven healthcare solutions. #M42 #FutureHealthSummit2026 #DigitalHealth #HealthcareInnovation #SmartHealth #AbuDhabi #FutureHealthAD

RT @ADMediaOffice: .@M42Health has launched Ossi, a multi-agent AI clinical platform powered by @Microsoft’s Azure technology during Abu Dhabi Future Health Summit 2026. Activated across seven M42 facilities, Ossi reduces clinical documentation and gives clinicians more time to focus on patient care.

RT @ADMediaOffice: .@M42Health has partnered with Siemens Healthineers during Abu Dhabi Future Health Summit 2026, combining population-scale digital health, digital infrastructure, and AI with advanced imaging and diagnostics to support earlier disease detection and prevention across the Global South.

RT @ADMediaOffice: .@M42Health’s @MHDubaiofficial and Tawam Molecular Imaging Centre have partnered with @ReCogHealth to expand access to specialised memory and brain health services in the UAE, supporting coordinated assessment, diagnosis, treatment, and follow-up care for cognitive conditions.